MARKET

OTLC

OTLC

Oncotelic Therapeutics Inc
OTCMQB
0.067
0.000
0.00%
Opening 09:30 10/04 EDT
OPEN
--
PREV CLOSE
0.067
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.338
52 WEEK LOW
0.054
MARKET CAP
25.84M
P/E (TTM)
4.085
1D
5D
1M
3M
1Y
5Y
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease, Pancreatic Cancer, and DIPG, today anno...
GlobeNewswire · 6d ago
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and DIPG, today announced that the Compa...
GlobeNewswire · 09/14 12:15
Oncotelic Therapeutics reports Q2 results
Oncotelic Therapeutics press release (<a href="https://seekingalpha.com/sy...
Seekingalpha · 08/22 14:00
BRIEF-Oncotelic Reports Q2 2022 Compared To Q2 2021 Financial Results
BRIEF-Oncotelic Reports Q2 2022 Compared To Q2 2021 Financial Results
Reuters · 08/22 13:08
Oncotelic Participating at Biotechgate Digital Partnering
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that...
GlobeNewswire · 08/17 12:00
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that...
GlobeNewswire · 07/12 11:00
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that...
GlobeNewswire · 06/15 11:00
Oncotelic gets FDA nod for mid-stage trial design for lead asset and Keytruda combo
Clinical-stage biotech Oncotelic Therapeutics (OTCQB:OTLC) announced on Wednesday that the Food and Drug Administration (FDA) cleared the Phase 2 trial protocol for the company’s lead candidate OT-101 in combination with
Seekingalpha · 05/25 11:24
More
About OTLC
Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug candidate, OT-101, is developed for the treatment of solid tumors with focus on brain cancer in adult and diffuse intrinsic pontine glioma (DIPG) in children. The Company’s OT-101 completed phase II for pancreatic cancer, melanoma, and glioblastoma. Its CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. The OXi4503 is developed for the treatment of liquid tumors with focus on childhood leukemia.

Webull offers kinds of Oncotelic Therapeutics Inc stock information, including OTCMQB:OTLC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLC stock methods without spending real money on the virtual paper trading platform.